FRESUBIN HEPA

Glavne informacije

  • Zaščiteno ime:
  • Fresubin Hepa Drink kapučino EasyBottle 200 ml 4x
  • Farmacevtska oblika:
  • peroralna suspenzija
  • Enote v paketu:
  • škatla s 4 plastenkami z 200 ml napitka (EasyBottle)
  • Uporabi za:
  • ljudje
  • Vrsta medicine:
  • Alopatska drog

Dokumentov

Lokalizacija

  • Na voljo v:
  • Fresubin Hepa Drink kapučino EasyBottle 200 ml 4x
    Slovenija
  • Jezik:
  • slovenščina

Terapevtski podatki

  • Terapevtska skupina:
  • Maščobe, ogljikovi hidrati, proteini, minerali in vitamini, kombinacije

Drugi podatki

Stanje

  • Source:
  • JAZMP - Javna agencija RS za zdravila in medicinske pripomočke - Slovenia Medicines Agency
  • Status dovoljenje:
  • Živilo
  • Zadnja posodobitev:
  • 18-01-2018

Podatki za bolnike

Fresubin Hepa DRINK

okus: kapučino

1,3 kcal/ml

vsebina: 4 x 200 ml (4 x 260 kcal/1100 kJ)

Dietetično

živilo

posebne

zdravstvene

namene.

Presnovi

prilagojen,

prehransko

popoln

visokokaloričen (1,3 kcal/ml) pripravek za pitje z majhno vsebnostjo vode, obogaten z razvejanimi

aminokislinami. Vsebuje malo natrija. Brez glutena, brez laktoze. Vsebuje sladila. Za dietetsko

uravnavanje

prehranjevanja

bolnikov

kronično

odpovedjo

jeter

obstoječo

grozečo

podhranjenostjo ali z motnjami hranjenja.

Odmerjanje: Kot edini vir prehrane ≥ 5-7 plastenk/dan, kot dopolnilna prehrana ≥ 2-3 plastenke/dan. Pijte

počasi. Živilo je najbolj okusno, če je ohlajeno.

Pomembna opozorila: Uporabljajte le pod zdravniškim nadzorom. Izdelek ni primeren za otroke do 3 let.

Vsebuje kofein (4,0 mg/100 ml). Pred uporabo dobro pretresite. Ni za parenteralno uporabo. Pakirano v

kontrolirani atmosferi.

Shranjevanje: Shranjujte pri sobni temperaturi. Odprte plastenke lahko shranjujete v hladilniku do 24 ur.

Povprečna vsebnost na 100 ml: energijska vrednost 550 kJ (130 kcal), maščobe 4,7 g (od tega nasičene

maščobne kisline 2,0 g, MCT 1,7 g, mononenasičene maščobne kisline 1,4 g, polinenasičene maščobne

kisline 1,3 g), ogljikovi hidrati 17,4 g (od tega sladkorji 0,7 g, laktoza ≤ 0,01 g), vlaknine 1,0 g, beljakovine

4,0 g (od tega razvejane aminokisline 1,93 g (44 %)), voda 78 ml, osmolarnost 360 mosmol/l.

Energijski deleži: maščobe 33 %, ogljikovi hidrati 53,5 %, vlaknine 1,5 %, beljakovine 12 %.

Minerali in elementi v sledovih: Na 75 mg (3,3mmol) (**), K 120,0 mg (3,1 mmol) (*6,0), Cl 71,5 mg

(2,0 mmol) (*8,9), Ca 80,0 mg (2,0 mmol) (*10,0), Mg 27,0 mg (1,1 mmol) (*7,2), P 53,0 mg (1,7 mmol)

(*7,6), Fe 1,33 mg (*9,5), Zn 1,2 mg (*12,0), Cu 130,0 µg (*13,0), Mn 0,27 mg (*13,5), I 13,3 µg (*8,9),

F 0,13 mg (*3,7), Cr 6,67 µg (*16,7), Mo 10 µg (*20,0), Se 6,67 µg (*12,1).

Vitamini: vit. A 70 µg (*8,8), β-karoten 130 µg (**), vit. D

1,0 µg (*20,0), vit. E 1,33 mg (*11,1), vit. K

6,67 µg (*8,9), vit. B

0,13 mg (*11,8), vit. B

0,17 mg (*12,1), niacin 1,6 mg (*10,0), vit. B

0,16 mg (*11,4),

vit. B

0,27 µg (*10,8), pantotenska kislina 0,47 mg (*7,8), biotin 5,0 µg (*10,0), folna kislina 27 µg (*13,5),

vit. C 6,67 mg (*8,3), holin 28 mg (**).

Sestavine: voda, maltodekstrin, rastlinska olja, nasičeni srednjeverižni trigliceridi (MCT), sojine beljakovine,

sojini polisaharidi, mlečne beljakovine, L-levcin, arome (vsebujejo pšenični maltodekstrin), L-valin, L-

argininijev klorid, L-izolevcin, kalijev citrat, natrijev citrat, kalcijev fosfat, magnezijev citrat, sladila (natrijev

ciklamat, natrijev saharinat), holinijev klorid, vit. C, sredstvo za uravnavanje kislosti (E330), magnezijev

oksid, kalcijev karbonat, železov sulfat, gostilo (E407), cinkov sulfat, niacin, manganov klorid, vit. E,

pantotenska kislina, natrijev fluorid, vit. B

, vit. B

, bakrov sulfat, vit. B

, vit. A, β-karoten, folna kislina,

kromov klorid, natrijev molibdat, natrijev selenit, kalijev jodid, vit. K

, biotin, vit. D

, vit. B

*delež (%) priporočenega dnevnega vnosa PDV (RDA); **PDV ni določen

Uporabno najmanj do konca: označeno na originalni ovojnini

Distributer: Medias International d.o.o., Leskoškova cesta 9D, 1000 Ljubljana

26-7-2018

Orphan designation:  Peretinoin,  for the: Treatment of hepatocellular carcinoma

Orphan designation: Peretinoin, for the: Treatment of hepatocellular carcinoma

Europe - EMA - European Medicines Agency

18-7-2018

Orphan designation:  Lenvatinib,  for the: Treatment of hepatocellular carcinoma

Orphan designation: Lenvatinib, for the: Treatment of hepatocellular carcinoma

Europe - EMA - European Medicines Agency

29-6-2018

Nieuwe behandeling tegen hepatitis C in het basispakket

Nieuwe behandeling tegen hepatitis C in het basispakket

Een nieuwe behandeling tegen chronische hepatitis C met het geneesmiddel Vosevi wordt vanaf 1 juli 2018 vergoed vanuit het basispakket. Dat heeft minister Bruno Bruins (Medische Zorg) besloten nadat hij met de fabrikant onderhandeld heeft over de prijs van het nieuwe middel. Vosevi kan worden ingezet bij alle patiënten met een chronische hepatitis C infectie. Met de opname van Vosevi zijn nu alle geneesmiddelen voor hepatitis C patiënten in Nederland beschikbaar vanuit het basispakket .

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

16-11-2017

Medicines Safety Update, Volume 8, Number 5, October-November 2017

Medicines Safety Update, Volume 8, Number 5, October-November 2017

Ibrutinib - ventricular tachyarrhythmia, hepatitis B reactivation and infection; Improving Product Information; Codeine-containing products - use in children and ultra-rapid metabolisers

Therapeutic Goods Administration - Australia

15-11-2012

Danish Pharmacovigilance Update, 18 October 2012

Danish Pharmacovigilance Update, 18 October 2012

In this issue of Danish Pharmacovigilance Update, read about: Risk of developing hepatotoxicity in patients undergoing treatment with agomelatine (Valdoxan®)

Danish Medicines Agency

19-9-2018

#FDA issues final guidance with recommendations for labeling and safety testing of #heparin  containing medical devices and device-led combination products to help  reduce the risk of patient injury. To read the guidance, click here:  https://go.usa.gov/x

#FDA issues final guidance with recommendations for labeling and safety testing of #heparin containing medical devices and device-led combination products to help reduce the risk of patient injury. To read the guidance, click here: https://go.usa.gov/x

#FDA issues final guidance with recommendations for labeling and safety testing of #heparin containing medical devices and device-led combination products to help reduce the risk of patient injury. To read the guidance, click here: https://go.usa.gov/xP2VB  #MedicalDevice pic.twitter.com/hsdX5ylKPu

FDA - U.S. Food and Drug Administration

13-9-2018

 European Medicines Agency stakeholder interaction on the development of medicinal products for chronic non-infectious liver diseases (PBC, PSC, NASH), European Medicines Agency, London, UK, From: 03-Dec-2018, To: 03-Dec-2018

European Medicines Agency stakeholder interaction on the development of medicinal products for chronic non-infectious liver diseases (PBC, PSC, NASH), European Medicines Agency, London, UK, From: 03-Dec-2018, To: 03-Dec-2018

This workshop on the development of medicines for chronic non-infectious liver diseases, including primary biliary cholangitis, primary sclerosing cholangitis and nonalcoholic steatohepatitis, provides a platform for discussion on appropriate endpoints including validation of surrogate endpoints/biomarkers, suitable study populations, potentially adequate trial designs and the specific challenges with paediatric medicine development. The workshop will support the drafting of a reflection paper on regul...

Europe - EMA - European Medicines Agency